🔧 Filters
Try: author name · keyword phrase · DOI
Original Article
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (PCSK9i) are highly effective lipid-lowering agents that reduce low-density lipoprotein cholesterol (LDL-C) by enhancing LD
PCSK9PCSK9iLDL-CAlirocumabEvolocumabFamilial hypercholesterolaemia
Original Article
Background: Dyslipidemia, characterized by abnormal blood lipid levels, is a major risk factor for cardiovascular disease, contributing to an estimated 4.2 million deaths and disabilities globally. Th
CholesterolDyslipidemiaHDLLDLLipid ProfileTriglycerides
Review Article
Atherosclerosis was found in humans who lived thousands years ago. Paleopathologist Marc Armand Ruffer (1859-1917) identified atherosclerotic plaques in the aorta as well as in several large arteries
AtheromaLipoproteinsLDL cholesterolAncient MedicineExperimental atherosclerosisMolecular Biology
Original Article
Background: Although statins remain the cornerstone of lipid-lowering therapy, LDL-C targets are often not achieved with statin monotherapy. This study evaluated the effectiveness and tolerability of
Dyslipidemialow-density lipoprotein cholesterolrosuvastatinezetimibecombination therapyatherosclerotic cardiovascular disease.
Original Article
Introduction: Pediatric metabolic screening is governed by a weight-centric dualism that prioritizes obesity while overlooking cardiometabolic risks in undernutrition. While obesity-related dyslipidem
Pediatric ObesityGrowth DisordersDyslipidemiasChild Health Services.
Original Article
Introduction: Lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). Despite known ethnic differences, Lp(a) data among UK Black popul
Lipoprotein(a)Point-of-care testingCardiovascular risk stratificationBlack populationAtherosclerotic cardiovascular disease. Community screening.